Biopharmaceutical News and Research

RSS

Study shows substantial benefit of combination therapy for advanced Marburg infections

A new study conducted at the Galveston National Laboratory at the The University of Texas Medical Branch at Galveston has shown substantial benefit to combining monoclonal antibodies and the antiviral remdesivir against advanced Marburg virus.

25 Mar 2021

Speakers Announced for Virtual Experimental Biology 2021 Meeting

Renowned scientists—including Nobel laureates, research pioneers, and celebrated educators—will speak at the virtual Experimental Biology (EB) 2021 meeting, to be held April 27–30.

23 Mar 2021

New method could drive down the production cost of antibodies

Antibody injections are a highly desirable treatment for people with chronic diseases such as cancer, psoriasis, Crohn's disease and arthritis. And recently, antibodies have been in the news as a promising treatment for severe cases of COVID-19.

22 Mar 2021

RedHill provides opaganib treatment under compassionate use exemption for Swiss COVID-19 patients

RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced that it has acted on a request to provide opaganib treatment on an outpatient basis under compassionate use exemption for several Swiss patients suffering from COVID-19 pneumonia.

22 Mar 2021

AstraZeneca's COVID-19 vaccine protects against symptomatic disease

Results from a large clinical trial in the United States and South America indicate that AstraZeneca's COVID-19 vaccine, AZD1222, is well-tolerated and protects against symptomatic COVID-19 disease, including severe disease or hospitalization.

22 Mar 2021

New antibiotic compound can effectively clear multi-drug resistant gonorrhea in animals

A new antibiotic compound clears infection of multi-drug resistant gonorrhea in mice in a single oral dose, according to a new study led by researchers at Penn State and Emory University.

19 Mar 2021

48Hour Discovery and Merck join hands to accelerate drug development

48Hour Discovery and CQDM are proud to announced that the company has been awarded $800,000 for peptide drug discovery using its patented drug discovery platform.

15 Mar 2021

Immune-modified ex vivo platform can measure treatment response of ovarian cancer

KIYATEC, Inc researchers demonstrated that their immune-modified ex vivo platform can measure treatment response through direct interaction between a patient's cancer and infiltrating immune cells, and immuno-oncology agents.

12 Mar 2021

Study: Monoclonal antibody 'cocktail' effective against all known COVID-19 variants

A monoclonal antibody "cocktail" developed at Vanderbilt University Medical Center (VUMC) to neutralize the COVID-19 virus is effective against all known strains, or variants, of the virus, according to a report published in the journal Nature Medicine.

5 Mar 2021

ACTIV-3 clinical trial evaluating investigational COVID-19 therapies closes enrollment in two sub-studies

The ACTIV-3 clinical trial, which is evaluating the safety and efficacy of investigational therapeutics for COVID-19 in hospitalized patients, has closed enrollment in two sub-studies: one examining the investigational monoclonal antibody therapy VIR-7831, and another evaluating the investigational combination monoclonal antibody therapy containing BRII-196 and BRII-198.

5 Mar 2021

Aptamer Group Extends Collaboration With Leading Biopharmaceutical Company to Explore Next-Generation Drug Delivery Approaches

Aptamer Group, the developer of Optimer™ reagents and therapeutics, today announced the extension of their current agreement with AstraZeneca, a global biopharmaceutical company. Image credit: Shutterstock.com/Billion Photos

From Aptamer Group 5 Mar 2021

Phase 1 clinical trial shows promising results for monoclonal antibodies against MERS coronavirus

A randomized, placebo-controlled Phase 1 clinical trial of two monoclonal antibodies (mAbs) directed against the coronavirus that causes Middle East respiratory syndrome (MERS) found that they were well tolerated and generally safe when administered simultaneously to healthy adults.

23 Feb 2021

UH receives funding from Gilead Sciences to fight against HIV/AIDS epidemic

A University of Houston Graduate College of Social Work research center working to eradicate the underlying serious and systemic challenges that contribute to the HIV/AIDS epidemic in the Southern United States has received $5 million in renewal funding from biopharmaceutical company Gilead Sciences, Inc. to facilitate the continuation of its impactful work.

22 Feb 2021

Intranasal COVID-19 vaccine candidate preclinically tested at UAB expected to start clinical trial

The Altimmune Inc. vaccine candidate that was tested preclinically at the University of Alabama at Birmingham last year is expected to start patient enrollment for its Phase 1 clinical trial next week.

20 Feb 2021

Can Pfizer and Moderna end the pandemic by sharing their vaccine designs? It’s not that simple

Vaccine makers Pfizer and Moderna earned praise for creating highly effective covid-19 vaccines in record time.

15 Feb 2021

SGD Pharma Takes Lead in Sustainability, Awarded Platinum EcoVadis Rating for The First Time

SGD Pharma, a leading supplier of glass primary packaging in the pharmaceutical industry, has been awarded a ‘platinum’ rating by EcoVadis, positioning it in the top 1% of all companies rated worldwide.

From SGD Pharma 5 Feb 2021

DSMB recommends continuation of Phase 2/3 study of opaganib for severe COVID-19

RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced that the independent Data Safety Monitoring Board (DSMB) for the global Phase 2/3 study of opaganib in patients with severe COVID-19, unanimously recommended to continue the study following a pre-scheduled futility review of unblinded efficacy data from the first 135 patients treated in the study and safety data from the first 175 patients.

30 Jan 2021

Gyros Protein Technologies introduces Gyrolab Bioaffy 4000 CD to extend sensitivity of immunoassay CD range

Gyros Protein Technologies AB today announced the introduction of Gyrolab® Bioaffy™ 4000 CD for immunoassay applications in biotherapeutic workflows.

From Gyros Protein Technologies AB 27 Jan 2021

New discovery could lead to faster and more effective treatments for chronic health complications

A world-first discovery by researchers at Monash University and The University of Queensland could lead to faster and more effective treatments for chronic health complications, such as cardiovascular disease and cancer, with 'fluorescent' in vivo biosensors.

26 Jan 2021

CytoDel successfully delivers neuronal antibody in animal models of botulism

CytoDel, Inc., a privately-held corporation, today announces the publication of preclinical data on the Company's lead product, Cyto-111, in the peer-reviewed journal, Science Translational Medicine. The complete text of the article titled, "Neuronal Delivery of Antibodies has Therapeutic Effects in Animal Models of Botulism," can be found here.

7 Jan 2021

Biopharmaceutical News and Research

Study shows substantial benefit of combination therapy for advanced Marburg infections

Speakers Announced for Virtual Experimental Biology 2021 Meeting

New method could drive down the production cost of antibodies

RedHill provides opaganib treatment under compassionate use exemption for Swiss COVID-19 patients

AstraZeneca's COVID-19 vaccine protects against symptomatic disease

New antibiotic compound can effectively clear multi-drug resistant gonorrhea in animals

48Hour Discovery and Merck join hands to accelerate drug development

Immune-modified ex vivo platform can measure treatment response of ovarian cancer

Study: Monoclonal antibody 'cocktail' effective against all known COVID-19 variants

ACTIV-3 clinical trial evaluating investigational COVID-19 therapies closes enrollment in two sub-studies

Aptamer Group Extends Collaboration With Leading Biopharmaceutical Company to Explore Next-Generation Drug Delivery Approaches

Phase 1 clinical trial shows promising results for monoclonal antibodies against MERS coronavirus

UH receives funding from Gilead Sciences to fight against HIV/AIDS epidemic

Intranasal COVID-19 vaccine candidate preclinically tested at UAB expected to start clinical trial

Can Pfizer and Moderna end the pandemic by sharing their vaccine designs? It’s not that simple

SGD Pharma Takes Lead in Sustainability, Awarded Platinum EcoVadis Rating for The First Time

DSMB recommends continuation of Phase 2/3 study of opaganib for severe COVID-19

Gyros Protein Technologies introduces Gyrolab Bioaffy 4000 CD to extend sensitivity of immunoassay CD range

New discovery could lead to faster and more effective treatments for chronic health complications

CytoDel successfully delivers neuronal antibody in animal models of botulism

Pittcon Highlights: Pharmaceutical & Biologic eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News